{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:19:40Z","timestamp":1792023580061,"version":"4.4.0"},"reference-count":41,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":365,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Surg. Oncol."],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1002\/jso.23781","type":"journal-article","created":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T10:04:14Z","timestamp":1409565854000},"page":"213-220","source":"Crossref","is-referenced-by-count":155,"title":["Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma"],"prefix":"10.1002","volume":"111","author":[{"given":"Lucas M.","family":"Boehm","sequence":"first","affiliation":[{"name":"Division of Surgical Oncology; Department of Surgery; Medical College of Wisconsin; Milwaukee Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thejus T.","family":"Jayakrishnan","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology; Department of Surgery; Medical College of Wisconsin; Milwaukee Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Miura","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology; Department of Surgery; Medical College of Wisconsin; Milwaukee Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Zacharias","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology; Department of Surgery; Medical College of Wisconsin; Milwaukee Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian M.","family":"Johnston","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology; Department of Surgery; Medical College of Wisconsin; Milwaukee Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran K.","family":"Turaga","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology; Department of Surgery; Medical College of Wisconsin; Milwaukee Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Clark","family":"Gamblin","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology; Department of Surgery; Medical College of Wisconsin; Milwaukee Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,9,1]]},"reference":[{"key":"10.1002\/jso.23781-BIB0001|jso23781-cit-0001","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/s-2004-828889","article-title":"The epidemiology of cholangiocarcinoma","volume":"24","author":"Shaib","year":"2004","journal-title":"Semin Liver Dis"},{"key":"10.1002\/jso.23781-BIB0002|jso23781-cit-0002","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.jhep.2014.01.021","article-title":"Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma","volume":"60","author":"Bridgewater","year":"2014","journal-title":"J Hepatol"},{"key":"10.1002\/jso.23781-BIB0003|jso23781-cit-0003","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jhep.2003.11.030","article-title":"Rising incidence of intrahepatic cholangiocarcinoma in the United States: A true increase","volume":"40","author":"Shaib","year":"2004","journal-title":"J Hepatol"},{"key":"10.1002\/jso.23781-BIB0004|jso23781-cit-0004","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0168-8278(02)00297-0","article-title":"Changing international trends in mortality rates for liver, biliary, and pancreatic tumours","volume":"37","author":"Khan","year":"2002","journal-title":"J Hepatol"},{"key":"10.1002\/jso.23781-BIB0005|jso23781-cit-0005","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1053\/jhep.2001.25087","article-title":"Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States","volume":"33","author":"Patel","year":"2001","journal-title":"Hepatology"},{"key":"10.1002\/jso.23781-BIB0006|jso23781-cit-0006","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/SLA.0b013e318176c4d3","article-title":"Intrahepatic cholangiocarcinoma: Rising frequency, improved survival, and determinants of outcome after resection","volume":"248","author":"Endo","year":"2008","journal-title":"Ann Surg"},{"key":"10.1002\/jso.23781-BIB0007|jso23781-cit-0007","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1067\/msy.2002.127555","article-title":"Improved survival in resected biliary malignancies","volume":"132","author":"Nakeeb","year":"2002","journal-title":"Surgery"},{"key":"10.1002\/jso.23781-BIB0008|jso23781-cit-0008","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.suronc.2007.08.010","article-title":"Palliation of hepatic tumors","volume":"16","author":"Cunningham","year":"2007","journal-title":"Surgl Oncol"},{"key":"10.1002\/jso.23781-BIB0009|jso23781-cit-0009","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(05)67530-7","article-title":"Cholangiocarcinoma","volume":"366","author":"Khan","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/jso.23781-BIB0010|jso23781-cit-0010","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1155\/2005\/565479","article-title":"The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: A systematic review","volume":"19","author":"Dingle","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"10.1002\/jso.23781-BIB0011|jso23781-cit-0011","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2217\/14796694.2.4.509","article-title":"Chemotherapy for advanced cholangiocarcinoma: What is standard treatment","volume":"2","author":"Mazhar","year":"2006","journal-title":"Future Oncol"},{"key":"10.1002\/jso.23781-BIB0012|jso23781-cit-0012","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/jso.23781-BIB0013|jso23781-cit-0013","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00270-006-0062-3","article-title":"Transarterial therapy for hepatocellular carcinoma: Which technique is more effective? A systematic review of cohort and randomized studies","volume":"30","author":"Marelli","year":"2007","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1002\/jso.23781-BIB0014|jso23781-cit-0014","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1002\/jso.23781-BIB0015|jso23781-cit-0015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1002\/jso.23781-BIB0016|jso23781-cit-0016","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1002\/jso.23781-BIB0017|jso23781-cit-0017","unstructured":"Chapter 7: Selecting studies and collecting data. In Higgins J, Deeks J, (eds) www.cochrane-handbook.org"},{"key":"10.1002\/jso.23781-BIB0018|jso23781-cit-0018","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"10.1002\/jso.23781-BIB0019|jso23781-cit-0019","unstructured":"Dean A Sullivan K Soe M: OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 2.3.1. In, 2011\/23\/06"},{"key":"10.1002\/jso.23781-BIB0020|jso23781-cit-0020","unstructured":""},{"key":"10.1002\/jso.23781-BIB0021|jso23781-cit-0021","first-page":"437","article-title":"Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy","volume":"24","author":"Kuhlmann","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1002\/jso.23781-BIB0022|jso23781-cit-0022","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0720-048X(01)00414-4","article-title":"Arterial chemoinfusion therapy through an implanted port system for patients with unresectable intrahepatic cholangiocarcinoma-initial experience","volume":"41","author":"Tanaka","year":"2002","journal-title":"Eur J Radiol"},{"key":"10.1002\/jso.23781-BIB0023|jso23781-cit-0023","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/annonc\/mdp029","article-title":"Regional chemotherapy for unresectable primary liver cancer: Results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival","volume":"20","author":"Jarnagin","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1002\/jso.23781-BIB0024|jso23781-cit-0024","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/COC.0b013e3181d2709a","article-title":"Phase I\/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301)","volume":"34","author":"Inaba","year":"2011","journal-title":"Am J Clin Oncol"},{"key":"10.1002\/jso.23781-BIB0025|jso23781-cit-0025","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/01.RVI.0000143768.60751.78","article-title":"Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: Initial experience in a single institution","volume":"16","author":"Burger","year":"2005","journal-title":"J Vasc Interv Radiol"},{"key":"10.1002\/jso.23781-BIB0026|jso23781-cit-0026","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1007\/s00270-007-9032-7","article-title":"Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma","volume":"30","author":"Herber","year":"2007","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1002\/jso.23781-BIB0027|jso23781-cit-0027","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11605-007-0312-y","article-title":"Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): A single-institution experience","volume":"12","author":"Gusani","year":"2008","journal-title":"J Gastrointest Surg"},{"key":"10.1002\/jso.23781-BIB0028|jso23781-cit-0028","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.clon.2007.12.007","article-title":"Hepatic arterial infusion of mitomycin C with degradable starch microspheres for unresectable intrahepatic cholangiocarcinoma","volume":"20","author":"Shitara","year":"2008","journal-title":"Clin Oncol (R Coll of Radiol)"},{"key":"10.1002\/jso.23781-BIB0029|jso23781-cit-0029","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.5009\/gnl.2010.4.S1.S82","article-title":"Multimodal oncological therapy comprising stents, brachytherapy, and regional chemotherapy for cholangiocarcinoma","volume":"4","author":"Andrasina","year":"2010","journal-title":"Gut liver"},{"key":"10.1002\/jso.23781-BIB0030|jso23781-cit-0030","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.crad.2010.11.002","article-title":"Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma","volume":"66","author":"Park","year":"2011","journal-title":"Clin Radiol"},{"key":"10.1002\/jso.23781-BIB0031|jso23781-cit-0031","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/cncr.25625","article-title":"Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: A 2-center study","volume":"117","author":"Kiefer","year":"2011","journal-title":"Cancer"},{"key":"10.1002\/jso.23781-BIB0032|jso23781-cit-0032","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1148\/radiol.12112142","article-title":"Intrahepatic cholangiocarcinoma treated with local-regional therapy: Quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response","volume":"264","author":"Halappa","year":"2012","journal-title":"Radiology"},{"key":"10.1002\/jso.23781-BIB0033|jso23781-cit-0033","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/ijc.26407","article-title":"Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success","volume":"131","author":"Vogl","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1002\/jso.23781-BIB0034|jso23781-cit-0034","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ejso.2013.03.010","article-title":"Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma-a single-center experience","volume":"39","author":"Scheuermann","year":"2013","journal-title":"Eur J Surg Oncol"},{"key":"10.1002\/jso.23781-BIB0035|jso23781-cit-0035","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00270-008-9336-2","article-title":"Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: Preliminary results","volume":"31","author":"Aliberti","year":"2008","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1002\/jso.23781-BIB0036|jso23781-cit-0036","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/cncr.23818","article-title":"Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: Results from a pilot study","volume":"113","author":"Ibrahim","year":"2008","journal-title":"Cancer"},{"key":"10.1002\/jso.23781-BIB0037|jso23781-cit-0037","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1245\/s10434-009-0777-x","article-title":"Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: A preliminary assessment of this novel treatment option","volume":"17","author":"Saxena","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1002\/jso.23781-BIB0038|jso23781-cit-0038","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00259-011-1736-x","article-title":"18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres","volume":"38","author":"Haug","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1002\/jso.23781-BIB0039|jso23781-cit-0039","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00270-011-0142-x","article-title":"Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: Factors associated with prolonged survival","volume":"35","author":"Hoffmann","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1002\/jso.23781-BIB0040|jso23781-cit-0040","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s00270-012-0463-4","article-title":"Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: Survival, efficacy, and safety study","volume":"36","author":"Rafi","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1002\/jso.23781-BIB0041|jso23781-cit-0041","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/ptj\/89.9.873","article-title":"Reprint-preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"89","author":"Moher","year":"2009","journal-title":"Phys Ther"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjso.23781","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/jso.23781","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T10:00:01Z","timestamp":1625306401000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.23781"}},"subtitle":["Hepatic Artery Therapy for Unresectable ICC"],"short-title":[],"issued":{"date-parts":[[2014,9,1]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"URL":"https:\/\/doi.org\/10.1002\/jso.23781","relation":{},"ISSN":["0022-4790"],"issn-type":[{"value":"0022-4790","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9,1]]}}}